Image Place holder

Michael Jain, MD, PhD

 
Specialty: Blood and Marrow Transplant and Cellular Immunotherapy
Program: Blood and Marrow Transplant and Cellular Immunotherapy

Overview

Dr. Michael Jain is an Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy. Dr. Jain earned his MD and PhD at McGill University in Montréal, in the province of Québec, Canada. His PhD in Cell Biology was completed under the supervision of Dr. John Bergeron. Dr Jain completed an Internal Medicine Residency and a Hematology Residency at the University of Toronto. He completed a Clinician Scientist Training Program and Clinical Fellowship in Lymphoma and Autologous Stem Cell Transplantation at Princess Margaret Cancer Center, University of Toronto. Dr. Jain’s clinical interests focus on treatment modalities for relapsed lymphoma, particularly stem cell transplantation and cellular and immunotherapies. His research interests include translational research in lymphoma and early-phase clinical trials. 


Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • Princess Margaret Cancer Center - Lymphoma and Autologous Stem Cell Transplantation

Residency:

  • University of Toronto - Internal Medicine
  • University of Toronto - Hematology

Medical School:

  • McGill University - MD/PhD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Frank MJ, Hossain NM, Bukhari A, Dean E, Spiegel JY, Claire GK, Kirsch I, Jacob AP, Mullins CD, Lee LW, Kong KA, Craig J, Mackall CL, Rapoport AP, Jain MD, Dahiya S, Locke FL, Miklos DB. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. J Clin Oncol. 2021 Sep.39(27):3034-3043. Pubmedid: 34133196.
  • Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, Hussaini MO, Gonzalez RJ, Mullinax JE, Rodriguez P, Conejo-Garcia J, Anasetti C, Davila ML, Locke FL. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021 May.137(19):2621-2633. Pubmedid: 33512407. Pmcid: PMC8120145.
  • Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021 Mar.5(5):1154-1163. Pubmedid: 33635333. Pmcid: PMC7948297.
  • Hoogland AI, Jayani RV, Collier A, Irizarry-Arroyo N, Rodriguez Y, Jain MD, Booth-Jones M, Hyland KA, James BW, Barata A, Bachmeier CA, Chavez JC, Khimani F, Krivenko GS, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Abidi M, Locke FL, Jim HSL. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Med. 2021 Mar.10(6):1936-1943. Pubmedid: 33641257. Pmcid: PMC7957158.
  • Mirza AS, Kumar A, Hashmi H, Garcia F, Logothetis CN, Darwin A, Faramand R, Reid K, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Nishihori T, Locke FL, Jain MD. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplant Cell Ther. 2021 Mar.27(3):242.e1-242.e6. Pubmedid: 33781520.
  • Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger CS, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Buecklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge WA, Ayuk F, Bachy E, Salles GA, Jain MD, Subklewe M. CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021 Jun. Pubmedid: 34166502.
  • Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, Nieder M, Perez L, Mishra A, Elmariah H, Davila M, Ochoa L, Alsina M, Lazaryan A, Bejanyan N, Hansen D, Jain M, Locke F, Liu H, Pidala J, Shah B, Mhaskar R. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Jul.27(7):620.e1-620.e9. Pubmedid: 33798768.
  • Figura NB, Robinson TJ, Sim AJ, Wang X, Cao B, Chavez JC, Shah BD, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu HD, Kim S, Locke FL, Jain MD. Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. Int J Radiat Oncol Biol Phys. 2021 Jul. Pubmedid: 34242714.
  • Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, Faramand R, Hansen D, Alsina M, Ochoa L, Davila M, Anasetti C, Pidala J, Bejanyan N. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. 2021 Jul. Pubmedid: 34329754.
  • Jain MD, Locke FL. Seeing the Light: CAR T-cell Targeting of Lambda-restricted B-cell Lymphomas. Clin Cancer Res. 2021 Aug. Pubmedid: 34417197.
  • Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, Pinilla-Ibarz J, Shah BD, Faramand R, Coghill AE, Davila ML, Dholaria BR, Jain MD, Locke FL. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021 Apr.106(4):978-986. Pubmedid: 32327504. Pmcid: PMC8017820.
  • Spiegel JY, Dahiya S, Jain MD, Tamaresis JS, Nastoupil L, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis LJ, Reagan P, Oluwole OO, McGuirk JP, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose J, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill B, Miklos DB. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021 Apr.137(13):1832-1835. Pubmedid: 33156925.
  • Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020 Sep.38(27):3119-3128. Pubmedid: 32401634. Pmcid: PMC7499611.
  • Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020 Sep.26(18):4823-4831. Pubmedid: 32669372. Pmcid: PMC7501265.
  • Hashmi H, Mirza AS, Darwin A, Logothetis C, Garcia F, Kommalapati A, Mhaskar RS, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Locke FL, Nishihori T, Jain MD. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020 Sep.4(17):4086-4090. Pubmedid: 32877523. Pmcid: PMC7479945.
  • Rushton CK, Arthur SE, Alcaide M, Cheung M, Jiang A, Coyle KM, Cleary KLS, Thomas N, Hilton LK, Michaud N, Daigle S, Davidson J, Bushell K, Yu S, Rys RN, Jain M, Shepherd L, Marra MA, Kuruvilla J, Crump M, Mann K, Assouline S, Connors JM, Steidl C, Cragg MS, Scott DW, Johnson NA, Morin RD. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Adv. 2020 Jul.4(13):2886-2898. Pubmedid: 32589730. Pmcid: PMC7362366.
  • Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, Bachmeier CA, Chavez JC, Nishihori T, Davila ML, Khimani F, Liu HD, Pinilla-Ibarz J, Shah BD, Jain MD, Balagurunathan Y, Locke FL. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 Jul.4(14):3268-3276. Pubmedid: 32702097. Pmcid: PMC7391155.
  • Jain MD, Lam R, Liu Z, Stubbins RJ, Kahlon A, Kansara R, Goswami R, Humar A, Prica A, Sehn LH, Slack GW, Crump M, Savage KJ, Peters AC, Kuruvilla J. Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder. Brit J Haematol. 2020 Apr.189(1):97-105. Pubmedid: 32068243.
  • Kharfan-Dabaja MA, Jain MD, Aulakh S, Ayala E, Zubair AC, Tun HW, Liu HD, Locke FL, Chavez JC. Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. Am J Hematol. 2019 Sep.94(9):E245-E247. Pubmedid: 31211433. Pmcid: PMC6917994.
  • Hashmi H, Bachmeier C, Chavez JC, Song J, Hussaini M, Krivenko G, Nishihori T, Kotani H, Davila ML, Locke FL, Jain MD. Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. Brit J Haematol. 2019 Oct.187(2):e35-e38. Pubmedid: 31410842.
  • Chavez JC, Jain MD, Kharfan-Dabaja MA. Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models. Hematol Oncol Stem Cell Ther. 2019 Jun.13(1):1-6. Pubmedid: 31202671.
  • Sim AJ, Jain MD, Figura N, Chavez JC, Shah BD, Khimani F, Lazarayan A, Krivenko G, Davila ML, Liu HD, Falchook AD, Dahiya S, Rapoport AP, Kim SU, Locke FL, Robinson TJ. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2019 Dec.105(5):1012-1021. Pubmedid: 31175906. Pmcid: PMC6872916.
  • Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, Lee DH, Zlotoff DA, Zhang L, Drobni ZD, Hassan MZO, Bassily E, Rhea I, Ismail-Khan R, Mulligan CP, Banerji D, Lazaryan A, Shah BD, Rokicki A, Raje N, Chavez JC, Abramson J, Locke FL, Neilan TG. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). J Am Coll Cardiol. 2019 Dec.74(25):3099-3108. Pubmedid: 31856966. Pmcid: PMC6938409.
  • Beaupierre A, Lundberg R, Marrero L, Jain M, Wang T, Alencar MC. Management Across Settings: An Ambulatory and Community Perspective for Patients Undergoing CAR T-Cell Therapy in Multiple Care Settings. Clin J Oncol Nurs. 2019 Apr.23(2):27-34. Pubmedid: 30880815.
  • Jain MD, Bachmeier CA, Phuoc VH, Chavez JC. Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. Ther Clin Risk Manag. 2018 May.14:1007-1017. Pubmedid: 29910620. Pmcid: PMC5987753.
  • Jain MD, Davila ML. Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies. Stem Cells. 2018 Jan.36(1):36-44. Pubmedid: 29024301.
  • Locke FL, Jain MD. Advances in aggressive lymphoma from the 2018 American Society of Clinical Oncology annual meeting: commentary. Clin Adv Hematol Oncol. 2018 Aug.16 Suppl 14(8):20-23. Pubmedid: 30300338.
  • Jain MD, Kuruvilla J. Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma. Drugs. 2017 Oct.77(15):1645-1655. Pubmedid: 28819821.
  • Jain MD, Tomlinson GA, Lam D, Liu J, Damaraju D, Detsky AS, Devine LA. Workplace-Based Assessment of Internal Medicine Resident Diagnostic Accuracy. J Grad Med Educ. 2014 Sep.6(3):532-535. Pubmedid: 26279781. Pmcid: PMC4535220.
  • Jain MD, Nikonova A. Methemoglobinemia from curing salt. CMAJ. 2013 Nov.185(16):E771. Pubmedid: 23670150. Pmcid: PMC3826356.
  • Smirle J, Au CE, Jain M, Dejgaard K, Nilsson T, Bergeron J. Cell biology of the endoplasmic reticulum and the Golgi apparatus through proteomics. Cold Spring Harb Perspect Biol. 2013 Jan.5(1):a015073. Pubmedid: 23284051. Pmcid: PMC3579394.
  • Jain MD, Cabrerizo-Sanchez R, Karkouti K, Yau T, Pendergrast JM, Cserti-Gazdewich CM. Seek and you shall find--but then what do you do? Cold agglutinins in cardiopulmonary bypass and a single-center experience with cold agglutinin screening before cardiac surgery. Transfus Med Rev. 2013 Apr.27(2):65-73. Pubmedid: 23375735.

Patient Comments
Overall Satisfaction
4.7

16 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments